SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 4c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight